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Introduction 
The high mortality associated with bleeding pep- 
tic ulcer is accounted for predominantly by the 
20% of patients who continue to bleed or rebleed 
after the initial bleeding ~. Complete neutraliza- 
tion of acid and pepsin appears to be crucial for 
control of rebleeding, the mode of action being 
prevention of dissolution of the clot which plugs 
the bleeding artery 2'3. Conventional therapies 
comprising H2 receptor antagonists and antacids 
have not been able to achieve sustained achlor- 
hydria 4'5. However, a combination of high dose 
cimetidine and continuous nasogastric antacid in- 
fusion was shown to do so in duodenal ulcer pa- 
tients 6. We recently utilized the same regimen in 
a randomized control trial to demonstrate hat it 
was effective in achieving achlorhydria even in pa- 
tients with peptic ulcer who were actively bleed- 
ing. Furthermore, intensive therapy led to control 
of bleeding in a higher proportion of patients 
with bleeding peptic ulcer as compared to con- 
ventional therapy. The results of that study are 
in press7; and are briefly summarized below. Of 
25 patients with bleeding peptic ulcer included 
in the study, 12 were given conventional therapy 
(control group) and 13 intensive therapy (treat- 
ment group). Conventional therapy consisted of 
50 mg ranitidine i.v. at 8-hour intervals whereas 
the intensive therapy consisted of 100 mg cime- 
tidine i.v. every hour plus a continuous nasogas- 
tric drip of a liquid antacid at the rate of 0.5 ml/ 
rain. Gastric pH was monitored every hour using 
a phenaphthazine pH paper strip. The results 
showed that the mean gastric pH attained in pa- 
tients in the treatment group was 7.88_+0.37 as 
compared to 5.00+0.55 in those of the control 
group; the pH values were >7 on 95% of occa- 
sions in the former as compared to 8.6% in the lat- 
ter. Also, final control of bleeding was achieved in 
a significantly larger proportion of patients in the 
treatment group than in the control group (92.3% 
vs 50%; P<0.05). 
Having become convinced of the efficacy of the 
intensive therapy, we employed this regimen rou- 
tinely in all subsequent patients with bleeding 
peptic ulcer and report our observations in the 
present communication. 
Materials and Methods 
A total of 75 patients with active bleeding from 
peptic ulcer admitted to the Gastroenterology 
Unit of our institution over a period of one and 
a half years were thus treated with the intensive 
therapy and the outcome was evaluated. Charac- 
teristics of the patients and of their ulcers were 
also correlated with the outcome in order to de- 
termine the factors associated with failure of con- 
trol of bleeding and hence the need for surgery. 
Statistical analysis 
Analysis was performed using Student's 't' test, 
chi square analysis and Wilcoxson rank sum test. 
A 'P' value of <.05 was taken as significant. 
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Table 1 Characteristics of patients and their ulcers treated with intensive therapy 
S. No. Characteristic Gastric ulcer (n=21) Duodenal ulcer (n=54) Total (n=75) 
1. Age (yr, mean_+ SD) 48.81 _+ 15.90 45.44_+ 17.14 46.39_+ 15.90 
2. Sex ratio (M:F) 4.1:1 3.8:1 4.6:1 
3. Hb at admission (G%, mean_+SD) 7.55+2.51 8.42_+8.21 8.16_+7.04 
4. NSAIDs users, No. (%) 4 (19%) 14 (25%) 18 (24%) 
5. Smokers, No. (%) 3 (14.1%) 21 (39.8%) 24 (32%) 
6. Size of ulcer (cm, mean+SD) 1.40_+0.56 1.71 _+2.88 1.62+2.44 
7. Patients withSRH, No.(%) 18 (85.7%) 26 (48.1%) 44 (58.6%) 
Hb = hemoglobin 
Table 2 Results of treatment with intensive therapy in patients with bleeding peptic ulcer 
S. No. Characteristic Gastric ulcer (n=21) Duodenal ulcer (n=54) Total (n=75) 
1. Success of therapy No. (%) 18 (84.6) 40 (72) 58 (75.4) 
2. Failure of therapy No. (%) 3 (15.4) 14 (28) 17 (24.6) 
a. Rebleeding 1 (4.7) 10 (18) 11 (14.3) 
b. Contd. bleeding 2 (9.4) 4 (7.2) 6 (7.8) 
3. Transfusion requirement (units, mean+SD) 3.10_+4.35 2.96_+2.96 2.99+3.35 
4. Hospital stay (days) 5.24_+3.02 7.37_+7.35 6.77_+6.48 
5. Mortality (%) 0 5.5 4 
Results 
Of 75 patients treated with intensive therapy, 21 
had gastric ulcers (GU) and 54 had duodenal ul- 
cers (DU). The demographic features and factors 
such as major bleeding, use of non-steroidal 
anti-inflammatory drugs (NSAIDs) and smoking 
were equally distributed among the two ulcer 
groups. Only the frequency of signs of recent 
hemorrhage (SRH) was somewhat more frequent 
in GU than in DU (Table 1). 
Control of bleeding was however, achieved in a 
equally high percentage of patients in both ulcer 
groups (75.4%) (Table 2). Seventeen patients in 
whom intensive therapy failed to control the 
bleeding were subjected to surgery. These pa- 
tients did not differ from those who responded to 
medical therapy (no surgery group) with regard 
to age, admission hemoglobin, percentage using 
NSAID, smoking history, and site and size of ul- 
cers (Table 3). A comparison of the ulcer char- 
acteristics in these patients with those in whom 
bleeding was controlled by treatment revealed 
that 87% of patients requiring surgery had SRH 
whereas only half of the patients not requiring 
surgery had SRH. Moreover, all three patients 
with a spurter required surgery whereas only 
56.2% of patients with a visible vessel at the ulcer 
base required surgery. Interestingly, 85.8% of pa- 
tients having an adherent clot had arrest of the 
bleeding with intensive therapy (Table 3). No side 
effects of drug therapy were encountered in any 
patient. Three of the operated patients died dur- 
ing the postoperative p riod, bringing the overall 
mortality to 4% in the total group of 75 patients. 
Discussion 
With final control of bleeding occurring in 75.4% 
of peptic ulcer patients with bleeding, the results 
of the prospective trial of the intensive regimen 
were quite as expected from our earlier random- 
ized controlled trial 7. Furthermore, they have 
instilled confidence in us that his intensive thera- 
peutic regimen is practical and can be utilized to 
advantage in any hospital setting. Only a quarter 
of the patients given the intensive therapy in the 
present series required emergency surgery with 
an overall mortality of 4%. Although we had no 
control group in the present series, these latter 
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Table 3 Patients requiring surgery versus those not requiring surgery: Characteristics of patients and their ulcers 
S. No. Characteristic Surgery (n=17) No surgery (n=58) 
1. Age (yr, mean_+SD) 50.00_+18.93 45.26_+16.44 
2. Hb at admission (g%, mean_+SD) 6.54-+2.40 7.71 _+2.78 
3. NSAID users, No. (%) 5 (29.4) 13 (22.1) 
4. Smokers, No. (%) 6 (34.8) 18 (30.6) 
5. Site of ulcer, No. (%) 
a. GU 3 (17.4) 18 (30.6) 
b. DU 14 (82.6) 40 (68.4) 
6. Size of ulcer (cm, mean_+SD) 1.26_+0.62 1.93_+4.19 
7. Patients with SRH, No. (%) (n=44)* 15 (87) 29 (49.3)** 
a. visible vessel (n=16) 9 (56.2) 7 (43.8) 
b. adherent clot (n=21) 3 (14.2) 18 (85.8) 
c. oozing (n=4) 0 4 (100) 
d. spurter (n=3) 3 (100) 0 
8. Mortality, No. (%) 3 (17.4) 0 
*:'n' under this column refers to the total no. of patients with 'SRH' 
**: P<0.005 
figures are very impressive compared to those of 
a series of 33 patients with bleeding peptic ulcer 
who were treated in the same unit with the con- 
ventional regimen during the year preceding the 
start of the controlled trial of the intensive regi- 
men; of those 33 patients, 15 (43.3%) required 
surgery with an overall mortality of 15.1% (un- 
published ata). We, therefore, believe that uti- 
lization of the intensive therapy has resulted in a 
substantial reduction in the need for emergency 
surgery and the overall mortality in our patients 
with bleeding peptic ulcer. 
A comparison of 17 patients who required sur- 
gery with 58 patients who responded to intensive 
medical therapy revealed that there was no differ- 
ence in the two groups as regards age, admission 
hemoglobin, percentage using NSAIDs, smoking 
history, and site and size of ulcers. Jones et a111 
similarly failed to show any correlation between 
these factors and the need for surgery. The ma- 
jority (87%) of patients in the 'surgery group' 
had SRH as compared to only 50% in those not 
requiring surgery. All patients with a sputter and 
half the patients with a visible vessel required 
surgery whereas 85.8% of patients with a clot on 
the ulcer base responded to medical treatment 
(Table 3). This is in conformity with the observa- 
tions made by other workers who have also found 
a significant increase in the incidence of rebleed- 
ing and need for surgery in patients with a visible 
vessel or spurter, but not in those with nonarterial 
stigmata such as an adherent clot 12. 
Sustained achlorhydria can thus clearly be 
maintained by using a continuous nasogastric 
antacid infusion with an hourly bolus intravenous 
cimetidine and with this treatment the rate of 
control of bleeding was higher and the need for 
surgery and the overall mortality lower in the 
treatment group. We therfore strongly recom- 
mend its use in clinical practice. 
Summary 
A controlled randomized study and a subsequent 
prospective therapeutic trial have demonstrated 
the efficacy of an intensive therapy comprising 
hourly intravenous injections of 100 mg of cime- 
tidine along with a continuous nasogastric infu- 
sion of a liquid antacid at the rate of 0.5 ml per 
minute in achieving achlorhydria and controll- 
ing bleeding in patients with bleeding peptic ul- 
cer. We recommend that this regimen should be 
routinely employed for treating patients with 
bleeding peptic ulcer, at least in center that do not 
practise topical therapeutic modalities for control 
of bleeding. 
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